National registry for people with myelofibrosis and anemia in Germany.

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

RHODOLITE is a national, prospective, open-label, longitudinal, non-interventional multicenter registry that follows people with primary or secondary myelofibrosis and anemia in routine clinical care across Germany. Patients are enrolled when they start or continue systemic MF treatment and clinical data on patient characteristics, molecular diagnostics, comorbidities, treatment sequences, and outcomes are recorded. Health-related quality of life and other patient-reported outcomes are collected regularly for up to three years, with planned longer-term follow-up through the GSG‑MPN Bioregistry. The registry excludes patients planning allogeneic stem cell transplantation or actively enrolled in interventional trials and aims to map real-world treatment patterns and outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Confirmed diagnosis of primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF) (Note: diagnosis according to WHO-2017, ICC-2022 or WHO-2022 or IWG-MRT criteria, respectively).
* Diagnosis of anemia at the time of enrollment as per individual, clinical assessment by the local physician.
* Start of first or subsequent systemic treatment for MF.
* Informed consent and registration for the GSG-MPN Bioregistry.
* Willingness and capability to participate in PRO assessment.
* Signed and dated informed consent form for RHODOLITE at the latest six weeks after start of the respective systemic MF treatment.

Exclusion Criteria:

* No systemic therapy for diagnosed primary or secondary MF.
* Planned allogenic stem cell transplantation (allo-SCT) or active participation in an interventional clinical trial.

Where it's running

• Multiple sites all over Germany
  Multiple Locations, Germany Recruiting

Study contacts

• Study coordinator: iOMEDICO AG
• Email: info@iomedico.com
• Phone: +4976115242

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• MPN PROGRESSion Registry — tracking symptoms, treatments, and disease progression in people with MPNs.

  Track long-term symptoms, treatments, and disease progression in adults with myeloproliferative neoplasms to see how these conditions evolve over time.

  Recruiting at 2 sites MPN Research Foundation · Chicago, Illinois and 1 other locations · NCT07362225

• Evaluating DISC-0974 for treating anemia in myelofibrosis patients

  This study tests if a new treatment called DISC-0974 can help people with myelofibrosis who have anemia feel better and improve their condition.

  Recruiting at 33 sites Phase 1/2 Disc Medicine, Inc · Gilbert, Arizona and 34 other locations · NCT05320198

• Combining Momelotinib and Luspatercept for Myelofibrosis Treatment

  This study is testing if combining two medications, momelotinib and luspatercept, can help people with myelofibrosis who need blood transfusions feel better and reduce their transfusion needs.

  Recruiting at 33 sites Phase 2 GlaxoSmithKline · Ann Arbor, Michigan and 32 other locations · NCT06517875

• Evaluating the safety and effectiveness of bomedemstat for blood disorders

  This study is trying to see how safe and effective bomedemstat is for people with blood disorders like essential thrombocythemia and myelofibrosis who have been doing well on the treatment for at least six months.

  Recruiting at 18 sites Phase 3 Merck Sharp & Dohme LLC · Ann Arbor, Michigan and 20 other locations · NCT06351631

• Pacritinib and Selinexor in JAK-inhibitor naive myelofibrosis with anemia and low platelets

  This trial tests whether combining pacritinib and selinexor helps patients with myelofibrosis who have anemia and low platelets and have not yet tried a JAK inhibitor.

  Recruiting Phase 2 Icahn School of Medicine at Mount Sinai · Westwood, Kansas and 2 other locations · NCT07447817

• Nelfinavir to improve anemia in people with myelofibrosis by restoring iron delivery to the bone marrow

  This trial tests whether the antiviral drug nelfinavir can help people with myelofibrosis and anemia by raising hemoglobin and lowering blood markers of fibrosis.

  Recruiting Phase 1/2 University of California, Irvine · Orange, California · NCT07281781

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.